Correction to: Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis

Item

Correction to: Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis

Frazer, R.
;
Arranz, J.
;
Estévez, S. V.
;
Parikh, O.
;
Krabbe, L. M.
;
Vasudev, N. S.
;
Doehn, C.
;
Marschner, N.
;
Waddell, T.
;
Ince, W.
... show 1 more

Citations

Google Scholar:

Altmetric:

Authors

Frazer, R.
Arranz, J.
Estévez, S. V.
Parikh, O.
Krabbe, L. M.
Vasudev, N. S.
Doehn, C.
Marschner, N.
Waddell, T.
Ince, W.
Goebell, P. J.

Affiliation

Velindre Cancer Centre, Cardiff, CF14 2TL, UK. ricky.frazer@wales.nhs.uk. Hospital General Universitario Gregorio Marañón, Madrid, Spain. Hospital Universitario Lucus Augusti (HULA), Lugo, Spain. Lancashire Teaching Hospitals NHS Foundation Trust, Chorley, UK. Klinik für Urologie, Vivantes Humboldt-Klinikum, Berlin, Germany. Leeds Institute of Medical Research at St James'S, Leeds, UK. Urologikum Lübeck, Lübeck, Germany. Clinical Research Institute IOMEDICO, Freiburg, Germany. The Christie NHS Foundation Trust, Manchester, UK. Department of Oncology, Cambridge University NHS Foundation Trust, Cambridge, UK. Uniklinik Erlangen, Urologische und Kinderurologische Klinik, Erlangen, Germany.

Date

2025

Collections

All Christie Publications

Show all metadata

Files

Found in UnPaywall

Adobe PDF, 636.2 KB

Type

Article

Citation

Frazer R, Arranz J, Estévez SV, Parikh O, Krabbe LM, Vasudev NS, et al. Correction to: Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis. Curr Oncol Rep. 2025 Jun;27(6):788-90. PubMed PMID: 40343688. Pubmed Central PMCID: PMC12227500. Epub 2025/05/09. eng.

URI

https://christie.openrepository.com/handle/10541/627618